Status:
COMPLETED
A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity
Lead Sponsor:
Pfizer
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: * how the study medicine, danug...
Eligibility Criteria
Inclusion
- Key
- 18 years of age or older
- Body mass index (BMI) of ≥25.0-45.4 kg/m2; and a total body weight \>50 kg (110 lb)
- Key
Exclusion
- Evidence or history of any clinically significant medical conditions or laboratory abnormality
- Any condition possibly affecting drug absorption
- Known intolerance/hypersensitivity to a GLP-1R agonist
Key Trial Info
Start Date :
August 23 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 18 2024
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT06568731
Start Date
August 23 2024
End Date
December 18 2024
Last Update
January 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, United States, 06511